Satralizumab

Phase 3Terminated

2 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Generalized Myasthenia Gravis

Conditions

Generalized Myasthenia Gravis

Trial Timeline

Oct 19, 2021 → Sep 2, 2024

NCT ID

NCT04963270

About Satralizumab

Satralizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for Generalized Myasthenia Gravis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04963270. Target conditions include Generalized Myasthenia Gravis.

What happened to similar drugs?

12 of 20 similar drugs in Generalized Myasthenia Gravis were approved

Approved (12) Terminated (2) Active (8)

✅Duloxetine + PlaceboEli LillyApproved

✅IxekizumabEli LillyApproved

✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved

✅EscitalopramAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅Alprazolam (Xanax) + PlaceboRocheApproved

✅Ziprasidone + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05503264	Phase 3	Recruiting	Sep 27, 2022	Dec 14, 2029	NMDAR Autoimmune Encephalitis
NCT05271409	Phase 3	Recruiting	Aug 30, 2022	Dec 31, 2028	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
NCT04963270	Phase 3	Terminated	Oct 19, 2021	Sep 2, 2024	Generalized Myasthenia Gravis

Competing Products

20 competing products in Generalized Myasthenia Gravis

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Cenobamate	Ono Pharmaceutical	Phase 3	47
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Ixekizumab	Eli Lilly	Approved	43
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Escitalopram	AbbVie	Approved	43
Adalimumab	AbbVie	Phase 3	40
Quetiapine fumarate + Paroxetine	AstraZeneca	Phase 3	40